CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) to a sell rating in a research report released on Thursday. Other analysts have also issued reports about the stock.

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines using its proprietary CRISPR/Cas9 platform, stands at a critical juncture as it navigates ...

Stifel analyst Benjamin Burnett lowered the firm’s price target on Crispr Therapeutics (CRSP) to $49 from $53 and keeps a Hold rating on the shares. The firm’s neutral thesis on the stock is ...

Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics CRSP. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected ...

Bayer is to set up a joint venture with CRISPR Therapeutics and acquire a minority stake in the firm, one of the pioneers in the potentially revolutionary gene-editing technology. The partnership ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” rating in a research report issued on Friday, Marketbeat ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other firms that soared on Friday. Wall Street finished mixed anew on Friday, as investors ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE ...